Srini Ramanathan, is Chief Development Officer at Aditum Bio. Most recently, Srini was Chief Development Officer at Roivant Sciences, where he oversaw R&D for asset diligence, intake, and creation of new biotechnology companies.

Previously, Srini was Senior Vice President of Research and Development Sciences and Site Head at Horizon Therapeutics in South San Francisco, where he led discovery and several scientific functions supporting preclinical and clinical development. He has held leadership positions at Abbvie and earlier at Gilead Sciences, where he served as Head of Clinical Pharmacology supporting clinical development across therapeutic areas. Srini has contributed to the approval of twelve medicines spanning virology, ophthalmology, and rheumatology.

Srini holds a PhD in Pharmaceutics from Rutgers University, MS in Pharmaceutics from Duquesne University, and BPharm (Hons) from the Birla Institute of Technology and Science, Pilani, in India.